With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
|Articles|April 13, 2022
Daily Medication Pearl: Maralixibat (Livmarli)
Author(s)Saro Arakelians, PharmD
Maralixibat (Livmarli) is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.
Advertisement
Medication Pearl of the Day: Maralixibat (Livmarli)
Indication: Maralixibat (Livmarli) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.
Insight:
- Dosing:The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before the first meal of the day.
- Dosage forms: Oral solution 9.5 mg of maralixibat per mL.
- Adverse events: Most common adverse reactions (≥5%) are diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding, and bone fractures.
- Mechanism of action: Maralixibat is a reversible inhibitor of IBAT. It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
- Manufacturer: Mirum Pharmaceuticals
Source
Advertisement
Related to this article
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.
The DAPA ACT HF-TIMI 68 analysis shows early, sustained congestion relief and rising diuretic efficiency through 2 months.
The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
3
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
4
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
5